Ab1674 #ACR22 HCQ in pregnancy is SAFE and Standard of Care! In Utero Exposure to HCQ does NOT ass w/ ocular toxicity: OCTs 5 yrs after birth 👀 PATCH study of HCQ to reduce CHB in pregnancy 18% CHB (historical) -> 7% treated risk OCT: retinal thickness nml at 5 yrs @RheumNow

Are TNFi or IL-6Ri safe in rheumatic irAEs from ICI Rx? Multiple big US centers retrospective: TNFi, IL-6Ri vs MTX p>0.05, but may be approx 2x risk of cancer progression Has made me more cautious about TNFi, IL-6Ri - use MTX when you can Lovely work! ABST1669 #ACR22 @RheumNow https://t.co/cfAT1pQZ7I

Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at cohort enriched for CV events. @RheumNow #ACR22 #LateBreaking

L06 #ACR22 ORAL Surveillance Updates! Composite of all ischemic CV events and HF did NOT show difference b/w TOFA vs TNFi But, MACE numerically higher with Tofa w/ h/o ASCVD Highest CV risk in TOFA 10 mg BID, 2/2 VTE risk Most important risk is pt's individual risks @RheumNow https://t.co/jPPX7f5GRE

Across extended MACE endpoints risk was numerically higher with tofacitinib vs TNFi in pts with a history of artherosclerotic CV disease (ASCVD). CV risk (MACE-8 with HF +VTE) was higher in the Tofa 10mg bd vs TNFi. Buch M #L06 https://t.co/lFXl2ywbZe #ACR22 @RheumNow

• Risk of Extended Major Adverse Cardiovascular Event Endpoints with Tofacitinib …

Nestor et al. HCQ <5mg/kg day assoc increased hospitalisation for SLE flare. aOR 4.41 (95% CI 1.50-12.98) @RheumNow #ACR22 Abstr#1654 https://t.co/I4bTu2DWaR https://t.co/jpOwHUTenk

• Hydroxychloroquine Dosing Less Than 5 Mg/kg/day Leads to Increased Hospitalizat…

Are we giving enough HCQ?🤔 Findings from the study of Dr J Nestor show that ⬇️dose HCQ (</= 5mkd or <400mg/day) is associated w/ ⬆️hospitalizations for #lupus (adj. OR 4.41; 3.48) #ACR22 @RheumNow ABST#1654 @rheumarhyme #ACRBest https://t.co/XCoZgbdOim

Ozen et al. Safety Opioids vs NSAIDs in RA. Similar risks except 2-fold increase in VTE with opioids. @RheumNow #ACR22 Abstr#1646 https://t.co/kWBf8t4TFh https://t.co/dxKoilOhFX

• Major Adverse Cardiovascular Events and Mortality with Opioids versus NSAIDs In…

Castrejon et al. Cancer risk with b/tsDMARD in BIOBADASER. Again not looking great for abatacept, Rate ratio vs TNFi 2.2 (1.4-3.2). Age-adjusted HR 1.6 (1.0-2.6) @RheumNow #ACR22 Abstr#1752 https://t.co/PvBq2O9qPv https://t.co/XBfistBMhW

• Cancer Risk in Patients with Rheumatic Diseases Exposed to Different Biologic a…

Low dose #glucocorticoids in rheumatic diseases can lower bone mass and increase # even 2.5 mg #prednisone. The change in #BMD was more predictive of fracture not absolute BMD. L01 #ACR22 #ACRBest @RheumNow https://t.co/MbTk0L4DoK

NSAIDs and CV risk in Inflammatory Arthritis Dr. Richard Conway discusses abstract 1207, being presented #ACR22 meeting. https://t.co/CjU2YbA3tk https://t.co/bHE4xw2IRF

• https://bit.ly/3WZ6P6D

In a prospective cohort where MTX was withheld for 1 week post COVID vaccine, antibodies higher than other DMARDs which were continued (mostly RTX/MMF). Good to see more direct data rather than having to extrapolate from flu. @RheumNow ABST0913 #ACR22 https://t.co/YphKywNJfA

• Impact of Disease-modifying Antirheumatic Drugs on Immunogenicity to COVID-19 V…